SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A, De Plaen E, Amar-Costesec A, Boon T. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992; 176: 14537.
  • 2
    Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Appella E, Rosenberg SA. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994; 180: 34752.
  • 3
    van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boel P, De Smet C, Traversari C, Townsend A, Boon T. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 1994; 24: 303843.
  • 4
    Kang X, Kawakami Y, El-Gamil M, Wang R, Sakaguchi K, Yannelli JR, Appella E, Rosenberg SA, Robbins PF. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. J Immunol 1995; 155: 13438.
  • 5
    Robbins PF, El-Gamil M, Li YF, Topalian SL, Rivoltini L, Sakaguchi K, Sakaguchi K, Appella E, Kawakami Y, Rosenberg SA. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J Immunol 1995; 154: 594450.
  • 6
    Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, Cascinelli N, Bourlond A, Vanwijck R, Humblet Y. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 1995; 63: 8835.
  • 7
    Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4: 3217.
  • 8
    Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 32832.
  • 9
    Hiratsuka H, Imamura M, Ishii Y, Kohama G, Kikuchi K. Immunohistologic detection of lymphocyte subpopulations infiltrating in human oral cancer with special reference to its clinical significance. Cancer 1984; 53: 245666.
  • 10
    Mouri T, Nakamura S, Ohyama Y, Matsuzaki G, Shinohara M, Kishihara K, Hiroki A, Oka M, Shirasuna K, Nomoto K. T cell receptor Vα and Vβ gene usage by tumour-infiltrating lymphocytes in oral squamous cell carcinoma. Cancer Immunol Immunother 1996; 43: 108.
  • 11
    Nakao M, Yamana H, Imai Y, Toh Y, Toh U, Kimura A, Yanoma S, Kakegawa T, Itoh K. HLA A2601-restricted CTLs recognize a peptide antigen expressed on squamous cell carcinoma. Cancer Res 1995; 55: 424852.
  • 12
    Shichijo S, Nakao M, Imai Y, Takasu H, Kawamoto M, Niiya F, Yang D, Toh Y, Yamana H, Itoh K. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med 1998; 187: 27788.
  • 13
    Kikuchi M, Nakao M, Inoue Y, Matsunaga K, Shichijo S, Yamana H, Itoh K. Identification of a SART-1-derived peptide capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes. Int J Cancer 1999; 81: 45966.
  • 14
    Kawamoto M, Shichijo S, Imai Y, Imaizumi T, Koga T, Yanaga H, Itoh K. Expression of the SART-1 tumor rejection antigen in breast cancer. Int J Cancer 1999; 80: 647.
  • 15
    Imaizumi T, Kuramoto T, Matsunaga K, Shichijo S, Yutani S, Shigemori M, Oizumi K, Itoh K. Expression of the tumor-rejection antigen SART1 in brain tumors. Int J Cancer 1999; 83: 7604.
  • 16
    Tanaka S, Tsuda N, Kawano K, Sakamoto M, Nishida T, Hashimoto T, Shichijo S, Kamura T, Itoh K. Expression of tumor-rejection antigens in gynecologic cancers. Jpn J Cancer Res 2000; 91: 117784.
  • 17
    Shintaku I, Kawagoe N, Yutani S, Hoshi S, Orikasa S, Yoshizumi O, Itoh K. Expression of the SART1 tumor rejection antigen in renal cell carcinoma. Urol Res 2000; 28: 17884.
  • 18
    Yamana H, Itoh K. Specific immunotherapy with cancer vaccines. Gan To Kagaku Ryoho 2000; 27: 147788.
  • 19
    Marrack P, Kappler J. The T cell receptor. Science 1987; 238: 10739.
  • 20
    Sensi M, Parmiani G. Analysis of TCR usage in human tumors: a new tool for assessing tumor-specific immune responses. Immunol Today 1995; 16: 58895.
  • 21
    Kimura A, Date Y, Sasazuki T. Work shop report: DNA typing of HLA-A gene. MHC IRS 1994; 1 (Suppl): 1822.
  • 22
    Ohyama Y, Nakamura S, Matsuzaki G, Shinohara M, Hiroki A, Oka M, Nomoto K. T-cell receptor Vα and Vβ gene use by infiltrating T cells in labial glands of patients with Sjögren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995; 79: 7307.
  • 23
    Ohyama Y, Nakamura S, Matsuzaki G, Shinohara M, Hiroki A, Fujimura T, Yamada A, Itoh K, Nomoto K. Cytokine messenger RNA expression in the labial salivary glands of patients with Sjögren's syndrome. Arthritis Rheum 1996; 39: 137684.
  • 24
    Kawamura E, Nakamura S, Sasaki M, Ohyama Y, Kadena T, Kumamaru W, Shirasuna K. Accumulation of oligoclonal T cells in the infiltrating lymphocytes in oral lichen planus. J Oral Pathol Med 2003; 32: 2829.
  • 25
    Currier JR, Yassai M, Robinsson MA, Gorski J. Molecular defects in TCRBV genes preclude thymic selection and limit the expressed TCR repertoire. J Immunol 1996; 157: 1705.
  • 26
    Manfras BJ, Rudert WA, Trucco M, Boehm BO. Analysis of the α/β T-cell receptor repertoire by competitive and quantitative family-specific PCR with exogenous standards and high resolution fluorescence based CDR3 size imaging. J Immunol Methods 1997; 210: 23549.
  • 27
    Manfras BJ, Terjung D, Boehm BO. Non-productive human TCR β chain genes represent V-D-J diversity before selection upon function: insight into biased usage of TCRBD and TCRBJ genes and diversity of CDR3 region length. Hum Immunol 1999; 60: 1090100.
  • 28
    Van Kerckhove C, Russell GJ, Deusch K, Reich K, Bhan AK, DerSimonian H, Brenner MB. Oligoclonality of human intestinal intraepithelial T cells. J Exp Med 1992; 175: 5763.
  • 29
    Yamamoto K, Sakoda H, Nakajima T, Kato T, Okubo M, Dohi M, Mizushima Y, Ito K, Nishioka K. Accumulation of multiple T cell clonotypes in the synovial lesions of patients with rheumatoid arthritis revealed by a novel clonality analysis. Int Immunol 1992; 4: 121923.
  • 30
    Sasaki M, Nakamura S, Ohyama Y, Shinohara M, Ezaki I, Hara H, Kadena T, Kishihara K, Yamamoto K, Nomoto K, Shirasuna K. Accumulation of common T cell clonotypes in the salivary glands of patients with human T lymphotropic virus type I-associated and idiopathic Sjögren's syndrome. J Immunol 2000; 164: 282331.
  • 31
    Shimizu K, Yamaguchi Y, Ohta K, Miyahara E, Toge T. Analysis of T cell receptors reactive with squamous cell carcinoma antigen SART-1 presented by the HLA-A24 molecule. Oncol Rep 2002; 9: 599605.
  • 32
    Benit P, Chanet R, Fabre F, Faye G, Fukuhara H, Sor F. Sequence of the sup61-RAD18 region on chromosome III of Saccharomyces cerevisiae. Yeast 1992; 8: 14753.
  • 33
    Nakao M, Shichijo S, Imaizumi T, Inoue Y, Matsunaga K, Yamada A, Kikuchi M, Tsuda N, Ohta K, Takamori S, Yamana H, Fujita H. Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL. J Immunol 2000; 164: 256574.
  • 34
    Yang D, Nakao M, Shichijo S, Sasatomi T, Takasu H, Matsumoto H, Mori K, Hayashi A, Yamana H, Shirouzu K, Itoh K. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res 1999; 59: 405663.
  • 35
    Ito M, Shichijo S, Tsuda N, Ochi M, Harashima N, Saito N, Ito K. Molecular basis of T cell-mediated recognition of pancreatic cancer cells. Cancer Res 2001; 61: 203846.